The human genome is comprised of billions of points of tiny genetic code. DNA sequencing enables researchers to decode these DNA fragments, helping uncover valuable genetic information that relates to our well-being. Until recently, though, the technology didn’t exist to accurately and quickly process, decode and analyze the human genome. In the last decade, DNA sequencing has been completely revolutionized.
Today, Next-Generation Sequencing (NGS) technology has made it possible to process and decode the entire human genome in as little as 24 hours. NGS technology enables unprecedented scalability and touches on all areas of DNA research, including whole genome sequencing and exome sequencing. These contemporary sequencing methods are much more sensitive, enabling clinicians and researchers alike to discover a greater volume of submicroscopic genetic mutations in our DNA.
NGS is the future of DNA research, and the applications for this technology have the potential for enhancing individualized patient care. NGS applications include:
Macrogen, Inc. was founded in 1997, and in 2005 Macrogen Corp. in the US was established. In 2012, Macrogen Corp. was established to provide advanced clinical sequencing services to U.S. patients and hospitals. In that time, we’ve become a leading bioscience research firm and our reputation in the industry is proof of our commitment to advanced human genomic sequencing.
As a CLIA-licensed research facility, we offer highly specialized sequencing services, utilizing the latest the latest next-generation sequencing. Additionally, the Macrogen team employs highly trained researchers who are the experts in their fields. Our next-generation sequencing services have been utilized by researchers from many prestigious institutions, including but not limited to: National Institute of Health (NIH), Food and Drug Administration (FDA), Stanford University, etc.